T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$2.11B |
| 2 |
Linde
LIN
|
+$1.34B |
| 3 |
American International
AIG
|
+$1.34B |
| 4 |
Marvell Technology
MRVL
|
+$1.28B |
| 5 |
TSS
Total System Services, Inc.
TSS
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.27B |
| 2 |
Eli Lilly
LLY
|
+$1.64B |
| 3 |
NVIDIA
NVDA
|
+$1.59B |
| 4 |
RHT
Red Hat Inc
RHT
|
+$1.55B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.88% |
| 2 | Healthcare | 16.96% |
| 3 | Financials | 13.79% |
| 4 | Consumer Discretionary | 13.57% |
| 5 | Industrials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
Akamai
AKAM
$18B
| $24M | ﹤0.01% |
299,806
+2,437
| +0.8% | +$188K |
|
1127
PUT
State Street SPDR EURO STOXX 50 ETF
FEZ
$4.56B
| $23.9M | ﹤0.01% |
+624,800
| New | +$23.5M |
|
1128
UDR
UDR
$12.1B
| $23.9M | ﹤0.01% |
532,970
+3,763
| +0.7% | +$169K |
|
1129
Lincoln Electric
LECO
$15.3B
| $23.8M | ﹤0.01% |
289,109
+1,400
| +0.5% | +$116K |
|
1130
Cactus
WHD
$5.82B
| $23.8M | ﹤0.01% |
717,970
-4,378
| -0.6% | -$152K |
|
|
BOLD
1131
DELISTED
Audentes Therapeutics, Inc
BOLD
| $23.7M | ﹤0.01% |
626,881
-163,987
| -21% | -$6.3M |
|
|
HBMD
1132
DELISTED
Howard Bancorp, Inc. Common Stock
HBMD
| $23.7M | ﹤0.01% |
1,563,667
-14,143
| -0.9% | -$201K |
|
1133
Hasbro
HAS
$13.5B
| $23.7M | ﹤0.01% |
223,971
-1,616
| -0.7% | -$159K |
|
1134
Rhythm Pharmaceuticals
RYTM
$8.15B
| $23.6M | ﹤0.01% |
1,072,041
+64,625
| +6% | +$1.63M |
|
1135
HF Sinclair
DINO
$16.2B
| $23.3M | ﹤0.01% |
504,318
+50,884
| +11% | +$2.27M |
|
1136
Natera
NTRA
$44.4B
| $23.2M | ﹤0.01% |
842,468
-100,137
| -11% | -$2.21M |
|
1137
J.M. Smucker
SJM
$12.8B
| $23.2M | ﹤0.01% |
201,217
+3,072
| +2% | +$375K |
|
|
VAR
1138
DELISTED
Varian Medical Systems, Inc.
VAR
| $23.1M | ﹤0.01% |
170,026
+551
| +0.3% | +$73.6K |
|
|
CATM
1139
DELISTED
Cardtronics plc Class A Ordinary Shares (UK)
CATM
| $23M | ﹤0.01% |
842,760
-321
| -0% | -$10.4K |
|
|
CCRN
1140
DELISTED
Cross Country Healthcare
CCRN
| $22.9M | ﹤0.01% |
2,444,031
-200
| -0% | -$1.54K |
|
|
CMA
1141
DELISTED
Comerica
CMA
| $22.7M | ﹤0.01% |
313,019
+5,910
| +2% | +$439K |
|
|
CTXS
1142
DELISTED
Citrix Systems Inc
CTXS
| $22.6M | ﹤0.01% |
230,760
+6,367
| +3% | +$625K |
|
1143
Jefferies Financial Group
JEF
$12.7B
| $22.6M | ﹤0.01% |
1,314,947
-1,352,611
| -51% | -$23.2M |
|
1144
W.W. Grainger
GWW
$61.7B
| $22.6M | ﹤0.01% |
84,171
| – | – |
|
1145
KBR
KBR
$4.75B
| $22.4M | ﹤0.01% |
899,156
-3,972
| -0.4% | -$88.9K |
|
1146
Universal Insurance Holdings
UVE
$1.18B
| $22.4M | ﹤0.01% |
801,666
-337
| -0% | -$9.87K |
|
1147
iShares Core S&P 500 ETF
IVV
$909B
| $22.3M | ﹤0.01% |
75,694
+25,984
| +52% | +$7.53M |
|
1148
Ovintiv
OVV
$17.1B
| $22.2M | ﹤0.01% |
866,290
-12,404
| -1% | -$387K |
|
1149
Seagate
STX
$208B
| $22.2M | ﹤0.01% |
470,118
-27,090
| -5% | -$1.26M |
|
1150
Gray Television
GTN
$512M
| $22.1M | ﹤0.01% |
1,348,278
+497
| +0% | +$9.85K |
|
Similar funds
T. Rowe Price Associates's Q2 2019 Portfolio in Review
As of Q2 2019, T. Rowe Price Associates held 2,600 positions worth $712B, up 4.7% from $680B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2019 filing shows 72 new, 1,394 increased, 949 reduced and 59 closed positions. Its largest new stake was Alcon: 36,020,796 shares worth $2.23B. The largest sale was UnitedHealth, an estimated $2.27B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2019 buy was Alcon: 36,020,796 shares worth $2.23B.
- T. Rowe Price Associates added most to Linde in Q2 2019, an estimated $1.34B increase.
- T. Rowe Price Associates's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $2.27B.
- T. Rowe Price Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $609M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $712B portfolio in Q2 2019.
- T. Rowe Price Associates opened 72 new positions and closed 59 in Q2 2019.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $712B.
Based on T. Rowe Price Associates's 13F filing for Q2 2019, filed 15 Aug 2019.